Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis

V. Barak, C. Selmi, M. Schlesinger, M. Blank, N. Agmon-Levin, I. Kalickman, M. Eric Gershwin, Y. Shoenfeld

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC) is a chronic cholestatic autoimmune liver disease characterized by selective destruction of the intrahepatic bile ducts and highly specific serum anti-mitochondrial autoantibodies (AMA). Several studies have attempted to determine the cytokine pattern characterizing PBC, yet no definitive data have been gathered. The present study was designed to evaluate pro-inflammatory cytokines (IL-1β, IL-6, TNFα), soluble IL-2 receptor (sIL-2R, e.g. soluble CD25), and complement components (C1q, C3, factor B, properdin) levels in sera from 84 patients with PBC and 41 controls. PBC was characterized by significantly higher levels of all pro-inflammatory cytokines when compared to controls; these included IL-1β (433.3 ± 13.2 vs. 316.6 ± 14.7 pg/ml, P < 0.001), IL-6 (701 ± 17.4 vs. 158 ± 22.5 pg/ml, P < 0.001), TNFα (3.38 ± 0.6 pg/ml vs. undetectable, P = 0.001), and sIL-2R (1527.1 ± 106 vs. 566.4 ± 28.7 U/ml, P < 0.001). Similarly, all complement components were also significantly higher in PBC compared to control sera. In conclusion, PBC sera manifest higher levels of sIL-2R and complement components and this may reflect a perpetuated immune activation. As expected, we also report that all major pro-inflammatory cytokine levels are enhanced in PBC. Further longitudinal analyses could demonstrate a correlation between these markers and disease stage or inflammatory activity, to predict histological staging, disease activity, and response to treatment.

Original languageEnglish (US)
Pages (from-to)178-182
Number of pages5
JournalJournal of Autoimmunity
Volume33
Issue number3-4
DOIs
StatePublished - Nov 2009

Fingerprint

Biliary Liver Cirrhosis
Interleukin-2 Receptors
Cytokines
Serum
Interleukin-1
Interleukin-6
Complement C1q
Intrahepatic Bile Ducts
Complement Factor B
Autoantibodies
Autoimmune Diseases
Liver Diseases

Keywords

  • Autoimmune cholangitis
  • Cytokines
  • PBC
  • Serum markers
  • T regulatory cells

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Barak, V., Selmi, C., Schlesinger, M., Blank, M., Agmon-Levin, N., Kalickman, I., ... Shoenfeld, Y. (2009). Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. Journal of Autoimmunity, 33(3-4), 178-182. https://doi.org/10.1016/j.jaut.2009.09.010

Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. / Barak, V.; Selmi, C.; Schlesinger, M.; Blank, M.; Agmon-Levin, N.; Kalickman, I.; Gershwin, M. Eric; Shoenfeld, Y.

In: Journal of Autoimmunity, Vol. 33, No. 3-4, 11.2009, p. 178-182.

Research output: Contribution to journalArticle

Barak, V, Selmi, C, Schlesinger, M, Blank, M, Agmon-Levin, N, Kalickman, I, Gershwin, ME & Shoenfeld, Y 2009, 'Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis', Journal of Autoimmunity, vol. 33, no. 3-4, pp. 178-182. https://doi.org/10.1016/j.jaut.2009.09.010
Barak, V. ; Selmi, C. ; Schlesinger, M. ; Blank, M. ; Agmon-Levin, N. ; Kalickman, I. ; Gershwin, M. Eric ; Shoenfeld, Y. / Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. In: Journal of Autoimmunity. 2009 ; Vol. 33, No. 3-4. pp. 178-182.
@article{0b09b26a6a4043a09caeeab30853000c,
title = "Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis",
abstract = "Primary biliary cirrhosis (PBC) is a chronic cholestatic autoimmune liver disease characterized by selective destruction of the intrahepatic bile ducts and highly specific serum anti-mitochondrial autoantibodies (AMA). Several studies have attempted to determine the cytokine pattern characterizing PBC, yet no definitive data have been gathered. The present study was designed to evaluate pro-inflammatory cytokines (IL-1β, IL-6, TNFα), soluble IL-2 receptor (sIL-2R, e.g. soluble CD25), and complement components (C1q, C3, factor B, properdin) levels in sera from 84 patients with PBC and 41 controls. PBC was characterized by significantly higher levels of all pro-inflammatory cytokines when compared to controls; these included IL-1β (433.3 ± 13.2 vs. 316.6 ± 14.7 pg/ml, P < 0.001), IL-6 (701 ± 17.4 vs. 158 ± 22.5 pg/ml, P < 0.001), TNFα (3.38 ± 0.6 pg/ml vs. undetectable, P = 0.001), and sIL-2R (1527.1 ± 106 vs. 566.4 ± 28.7 U/ml, P < 0.001). Similarly, all complement components were also significantly higher in PBC compared to control sera. In conclusion, PBC sera manifest higher levels of sIL-2R and complement components and this may reflect a perpetuated immune activation. As expected, we also report that all major pro-inflammatory cytokine levels are enhanced in PBC. Further longitudinal analyses could demonstrate a correlation between these markers and disease stage or inflammatory activity, to predict histological staging, disease activity, and response to treatment.",
keywords = "Autoimmune cholangitis, Cytokines, PBC, Serum markers, T regulatory cells",
author = "V. Barak and C. Selmi and M. Schlesinger and M. Blank and N. Agmon-Levin and I. Kalickman and Gershwin, {M. Eric} and Y. Shoenfeld",
year = "2009",
month = "11",
doi = "10.1016/j.jaut.2009.09.010",
language = "English (US)",
volume = "33",
pages = "178--182",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",
number = "3-4",

}

TY - JOUR

T1 - Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis

AU - Barak, V.

AU - Selmi, C.

AU - Schlesinger, M.

AU - Blank, M.

AU - Agmon-Levin, N.

AU - Kalickman, I.

AU - Gershwin, M. Eric

AU - Shoenfeld, Y.

PY - 2009/11

Y1 - 2009/11

N2 - Primary biliary cirrhosis (PBC) is a chronic cholestatic autoimmune liver disease characterized by selective destruction of the intrahepatic bile ducts and highly specific serum anti-mitochondrial autoantibodies (AMA). Several studies have attempted to determine the cytokine pattern characterizing PBC, yet no definitive data have been gathered. The present study was designed to evaluate pro-inflammatory cytokines (IL-1β, IL-6, TNFα), soluble IL-2 receptor (sIL-2R, e.g. soluble CD25), and complement components (C1q, C3, factor B, properdin) levels in sera from 84 patients with PBC and 41 controls. PBC was characterized by significantly higher levels of all pro-inflammatory cytokines when compared to controls; these included IL-1β (433.3 ± 13.2 vs. 316.6 ± 14.7 pg/ml, P < 0.001), IL-6 (701 ± 17.4 vs. 158 ± 22.5 pg/ml, P < 0.001), TNFα (3.38 ± 0.6 pg/ml vs. undetectable, P = 0.001), and sIL-2R (1527.1 ± 106 vs. 566.4 ± 28.7 U/ml, P < 0.001). Similarly, all complement components were also significantly higher in PBC compared to control sera. In conclusion, PBC sera manifest higher levels of sIL-2R and complement components and this may reflect a perpetuated immune activation. As expected, we also report that all major pro-inflammatory cytokine levels are enhanced in PBC. Further longitudinal analyses could demonstrate a correlation between these markers and disease stage or inflammatory activity, to predict histological staging, disease activity, and response to treatment.

AB - Primary biliary cirrhosis (PBC) is a chronic cholestatic autoimmune liver disease characterized by selective destruction of the intrahepatic bile ducts and highly specific serum anti-mitochondrial autoantibodies (AMA). Several studies have attempted to determine the cytokine pattern characterizing PBC, yet no definitive data have been gathered. The present study was designed to evaluate pro-inflammatory cytokines (IL-1β, IL-6, TNFα), soluble IL-2 receptor (sIL-2R, e.g. soluble CD25), and complement components (C1q, C3, factor B, properdin) levels in sera from 84 patients with PBC and 41 controls. PBC was characterized by significantly higher levels of all pro-inflammatory cytokines when compared to controls; these included IL-1β (433.3 ± 13.2 vs. 316.6 ± 14.7 pg/ml, P < 0.001), IL-6 (701 ± 17.4 vs. 158 ± 22.5 pg/ml, P < 0.001), TNFα (3.38 ± 0.6 pg/ml vs. undetectable, P = 0.001), and sIL-2R (1527.1 ± 106 vs. 566.4 ± 28.7 U/ml, P < 0.001). Similarly, all complement components were also significantly higher in PBC compared to control sera. In conclusion, PBC sera manifest higher levels of sIL-2R and complement components and this may reflect a perpetuated immune activation. As expected, we also report that all major pro-inflammatory cytokine levels are enhanced in PBC. Further longitudinal analyses could demonstrate a correlation between these markers and disease stage or inflammatory activity, to predict histological staging, disease activity, and response to treatment.

KW - Autoimmune cholangitis

KW - Cytokines

KW - PBC

KW - Serum markers

KW - T regulatory cells

UR - http://www.scopus.com/inward/record.url?scp=71649095850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71649095850&partnerID=8YFLogxK

U2 - 10.1016/j.jaut.2009.09.010

DO - 10.1016/j.jaut.2009.09.010

M3 - Article

C2 - 19846277

AN - SCOPUS:71649095850

VL - 33

SP - 178

EP - 182

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

IS - 3-4

ER -